Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mary Hoffman

Nurse Practitioner, Family Merrillville, IN Nurse Practitioner

NPI 1386277564 CMS profile 10956236

200 E 89Th Ave, Merrillville, IN 46410

Open in the dashboard

General payments

$18,532

813 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary Hoffman of Merrillville, IN is reported in the CMS Open Payments database as having received $18,532 across 813 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,432 165
2024 General $3,192 174
2023 General $4,208 161
2022 General $2,815 159
2021 General $4,885 154

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Hoffman
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Mary Hoffman were reported at $3,432. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Mary Hoffman Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $4,885 $124 $35–$379 $132
2022 $2,815 $141 $44–$430 $149
2023 $4,208 $154 $49–$476 $160
2024 $3,192 $165 $51–$504 $164
2025 $3,432 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Biogen, Inc. $3,367 81 payments
  2. Novartis Pharmaceuticals Corporation $1,440 128 payments
  3. LivaNova USA, Inc. $1,313 10 payments
  4. AbbVie, Inc. $1,253 66 payments
  5. EMD Serono, Inc. $773 35 payments
  6. Neurocrine Biosciences, Inc. $682 24 payments
  7. Lilly USA, LLC $633 31 payments
  8. Celgene Corporation $603 26 payments
  9. Teva Pharmaceuticals USA, Inc. $551 29 payments
  10. Alexion Pharmaceuticals, Inc. $526 17 payments
  11. Other $7,391 366 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,886 808 payments
  2. Consulting Fee $1,707 3 payments
  3. Travel and Lodging $939 2 payments
Products named General payments · program years 2021–2025
  1. VNS Therapy $1,149 3 payments
  2. TYSABRI $1,036 47 payments
  3. ADUHELM $912 7 payments
  4. KESIMPTA $895 81 payments
  5. NURTEC ODT $658 20 payments
  6. VUMERITY Neurology $628 31 payments
  7. ZEPOSIA $603 26 payments
  8. VUMERITY Neurology $602 28 payments
  9. QULIPTA $560 30 payments
  10. UBRELVY $553 27 payments
  11. Other $11,353 639 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

1,697

Median for Nurse Practitioner: 389

Drug cost

$295,863

Median for Nurse Practitioner: $21,885

Branded share of claims

30.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 68 $68,414
Emgality Pen Galcanezumab-Gnlm Brand 84 $58,017
Qulipta Atogepant Brand 30 $34,510
Nurtec Odt Rimegepant Sulfate Brand 26 $28,855
Aimovig Autoinjector Erenumab-Aooe Brand 23 $17,020
Fycompa Perampanel Brand 12 $15,154
Keppra Levetiracetam Brand 12 $14,702
Zembrace Symtouch Sumatriptan Succinate Brand 14 $10,833
Ajovy Autoinjector Fremanezumab-Vfrm Brand 13 $9,365
Lamictal Lamotrigine Brand 13 $7,116

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$20,789

Medicare's payments for the services billed

Medicare patients

203

Average age 74

Services billed

372

131 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Alzheimer's or dementia 51%
Depression 50%
Diabetes 39%
COPD 36%
Ischemic heart disease 35%
Heart failure 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 39 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
$302 — —
BAFIERTAM
$211 — —
ZEPOSIA
$210 — —
Leqembi
$147 — —
BOTOX
$137 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 39 with Patron

Records

813 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record